Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketdailypress.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketDailyPress.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent DCGO Stock Price: $3.35
Summary: DocGo Inc. is a provider of last-mile telehealth and integrated medical mobility services. DocGo Inc., formerly known as Motion Acquisition Corp., is based in NEW YORK.
Richard Close analyst at Canaccord Genuity reiterates coverage on DocGo Inc. (DCGO) stock in the energy sector with a Buy rating and has set DCGO's stock price target at $10.
TipRanks.com reports that DocGo Inc. currently has 5 analysts offering 12-month price targets on DCGO and the consensus is a Buy rating with an average stock price target of $10.40. The most recent DCGO stock price we have is $3.35 and we are not making any DCGO forecasts at this time.
In addition, TradingView issued a rating for DCGO over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DCGO. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DCGO, please click here >>
Poseida Therapeutics, Inc., PSTX
Recent PSTX Stock Price: $2.79
Summary: Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Poseida Therapeutics Inc. is based in San Diego, California.
Arthur He analyst at H.C. Wainwright reiterates coverage on Poseida Therapeutics, Inc. (PSTX) stock in the energy sector with a Buy rating and has set PSTX's stock price target at $20.
TipRanks.com reports that Poseida Therapeutics, Inc. currently has 4 analysts offering 12-month price targets on PSTX and the consensus is a Buy rating with an average stock price target of $14.00. The most recent PSTX stock price we have is $2.79 and we are not making any PSTX forecasts at this time.
In addition, TradingView issued a rating for PSTX over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PSTX. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on PSTX, please click here >>
Inozyme Pharma, Inc., INZY
Recent INZY Stock Price: $5.24
Summary: Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts.
Joseph Stringer analyst at Needham reiterates coverage on Inozyme Pharma, Inc. (INZY) stock in the energy sector with a Buy rating and has set INZY's stock price target at $23.
TipRanks.com reports that Inozyme Pharma, Inc. currently has 4 analysts offering 12-month price targets on INZY and the consensus is a Buy rating with an average stock price target of $22.75. The most recent INZY stock price we have is $5.24 and we are not making any INZY forecasts at this time.
In addition, TradingView issued a rating for INZY over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on INZY. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on INZY, please click here >>
Nurix Therapeutics, Inc., NRIX
Recent NRIX Stock Price: $15.69
Summary: Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.
Gil Blum analyst at Needham reiterates coverage on Nurix Therapeutics, Inc. (NRIX) stock in the energy sector with a Buy rating and has set NRIX's stock price target at $31.
TipRanks.com reports that Nurix Therapeutics, Inc. currently has 5 analysts offering 12-month price targets on NRIX and the consensus is a Buy rating with an average stock price target of $25.00. The most recent NRIX stock price we have is $15.69 and we are not making any NRIX forecasts at this time.
In addition, TradingView issued a rating for NRIX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NRIX. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NRIX, please click here >>
The editors at marketdailypress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketDailyPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketDailyPress.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================